<DOC>
	<DOCNO>NCT01708629</DOCNO>
	<brief_summary>The purpose study assess safety efficacy brodalumab two different dos compare placebo participant moderate severe plaque psoriasis . A second purpose study assess safety efficacy brodalumab two different dos compare ustekinumab participant moderate severe plaque psoriasis . A third purpose study assess safety efficacy 4 maintenance regimen brodalumab .</brief_summary>
	<brief_title>Study Efficacy Safety Brodalumab Compared With Placebo Ustekinumab Moderate Severe Plaque Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject stable moderate severe plaque psoriasis least 6 month Subject involve body surface area ( BSA ) ≥ 10 % , PASI ≥ 12 , sPGA ≥ 3 screen baseline Subject diagnose erythrodermic psoriasis , pustular psoriasis , guttate psoriasis , medicationinduced psoriasis , skin condition ( eg , eczema ) would interfere study evaluation Subject know history Crohn 's disease Subject significant concurrent medical condition laboratory abnormality , define study protocol Subject stop use certain psoriasis therapy define study protocol Subject previously use ustekinumab antiIL17 biologic therapy Subject pregnant breastfeeding , plan become pregnant enrol study Female subject unwilling use highly effective method birth control unless 2 year postmenopausal surgically sterile</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>psoriasis , brodalumab , AMG 827</keyword>
</DOC>